Evrópusambandið - íslenska - EMA (European Medicines Agency)

mylan ireland limited - sugammadex sodium - taugakerfi - Öll önnur lækningavörur - reversal of neuromuscular blockade induced by   rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - sugammadex sodium - taugakerfi - Öll önnur lækningavörur - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

aop orphan pharmaceuticals gmbh - sugammadex sodium - taugakerfi - Öll önnur lækningavörur - afturköllun taugavöðvablokkunar sem valdið er af rócuronium eða vecuronium. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

piramal critical care b.v. - sugammadex sodium - taugakerfi - sugammadex - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

extrovis eu ltd. - sugammadex sodium - taugakerfi - Öll önnur lækningavörur - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - tocilizúmab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - Ónæmisbælandi lyf - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

medice arzneimittel pütter gmbh co. kg - epóetín alfa - anemia; kidney failure, chronic; cancer - sýklalyf - meðferð einkennum blóðleysi í tengslum við langvarandi nýrnabilun (crf) í fullorðna og börn sjúklingum:meðferð blóðleysi í tengslum við langvarandi nýrnabilun í börn og fullorðinn sjúklinga á blóðskiljun og fullorðinn sjúklinga á kviðarholi himnuskiljun;meðferð alvarlega blóðleysi af skert uppruna í fylgd með einkenni í fullorðinn sjúklinga með nýrnabilun ekki enn farið himnuskiljun. meðferð blóðleysi og lækkun blóðgjöf kröfur í fullorðinn sjúklingar fá lyfjameðferð fyrir traustan æxli, illkynja eitlaæxli eða margar forráðamenn, og í hættu á blóðgjöf eins og metnar af sjúklings almennt stöðu (e. hjarta stöðu, fyrirfram núverandi blóðleysi á að byrja í lyfjameðferð). alfa getur verið notuð til að auka afrakstur samgena blóð úr sjúklingar í predonation áætluninni. Þess að nota í þessu vísbending verður að vera rólegur gegn tilkynnt hættu segareki atburðum. meðferð aðeins ætti að gefa sjúklingum með meðallagi blóðleysi (tilkynnt (hb) 10-13 g/internet [6. 2-8. 1 mmól/l], nei járn skort), ef blóð bjarga málsmeðferð er ekki í boði eða ófullnægjandi þegar áætlað helstu skurðaðgerð þarf mikið magn af blóði (4 eða meira einingar af blóði fyrir konur eða 5 eða meira einingar fyrir karla). alfa getur verið notuð til að draga úr útsetningu ósamgena blóðgjafir í fullorðinn ekki járn skortir sjúklinga áður en meiriháttar val orthopaedic aðgerð, hafa miklar skynja hættu fyrir blóðgjöf fylgikvillar. nota ætti að vera bundin við sjúklinga með meðallagi blóðleysi (e. hb 10-13 g/internet) sem hafa ekki samgena predonation áætluninni í boði og með ráð blóðmissi 900 að 1800 ml.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

sandoz gmbh - epóetín alfa - anemia; kidney failure, chronic - sýklalyf - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients: , treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;, treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis;, treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e. hjarta stöðu, fyrirfram núverandi blóðleysi á að byrja í lyfjameðferð).

Evrópusambandið - íslenska - EMA (European Medicines Agency)

hexal ag - epóetín alfa - anemia; kidney failure, chronic; cancer - sýklalyf - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients: , treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;, treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. meðferð blóðleysi og lækkun blóðgjöf kröfur í fullorðinn sjúklingar fá lyfjameðferð fyrir traustan æxli, illkynja eitlaæxli eða margar forráðamenn, og í hættu á blóðgjöf eins og metnar af sjúklings almennt stöðu (e. hjarta stöðu, fyrirfram núverandi blóðleysi á að byrja í lyfjameðferð).

Evrópusambandið - íslenska - EMA (European Medicines Agency)

biolitec pharma ltd - temóporfín - head and neck neoplasms; carcinoma, squamous cell - Æxlishemjandi lyf - foscan er ætlað fyrir líknandi meðferð sjúklinga með langt höfðinu og hálsinn æxli klefi krabbamein ekki fyrir meðferð og við hæfi fyrir geislameðferð, aðgerð eða almenn lyfjameðferð.